Quick Evidence Summary
| Evidence type | Current status |
|---|---|
| Preclinical research | Animal models (rodents and others) on wound healing, tissue repair, and cardiac tissue recovery |
| Peer-reviewed human clinical trials | None specific to the TB-500 fragment; early-phase trials exist for the full-length parent molecule, Thymosin Beta-4 |
| Anecdotal human reports | Widespread online, but uncontrolled and self-reported |
| Mechanistic plausibility | Reasonably strong, based on actin regulation and angiogenesis pathways |
| Regulatory status | Sold as a research chemical for laboratory research use only |
What TB-500 Is
TB-500 is a synthetic version of a fragment of Thymosin Beta-4, a naturally occurring peptide involved in cell migration, wound healing, and angiogenesis (blood vessel formation). Because it's derived from a fragment of a larger, naturally occurring molecule, understanding TB-500's evidence base means keeping two separate research threads straight, one on the fragment and one on the parent molecule, which is exactly what the rest of this article walks through.
Human Evidence
This is the section where the distinction between TB-500 and Thymosin Beta-4 matters most, and it's easy to get wrong if you're skimming. The TB-500 fragment itself, the shorter peptide sold in the research chemical and peptide research community, has not been the specific subject of dedicated, published human clinical trials. There's no controlled human trial data that tested this fragment directly.
What does exist is a body of early-phase human clinical trial work on Thymosin Beta-4, the full-length molecule that TB-500 is derived from. Those trials, run under a separate research program, have explored applications including chronic wound healing, such as diabetic foot ulcers and pressure ulcers, along with dry eye conditions. That's real human trial data, but it was collected on a different molecule than the one most people mean when they refer to TB-500.
Why this matters: claims about TB-500's effects in humans are typically extrapolated from two separate sources, animal data on the fragment itself, and human data on the different, full-length Thymosin Beta-4 molecule. Neither source is direct human evidence for the fragment as sold, and conflating the two overstates what's actually been shown.
Preclinical (Animal) Evidence
The preclinical research base for TB-500 is predominantly animal-based. Studies in rodents and other animal models have examined the fragment for wound healing, tissue repair, and cardiac tissue recovery following injury. This is the primary evidence source specific to the TB-500 fragment itself, since, as covered above, dedicated human trials on the fragment do not exist.
Mechanistic Rationale
Thymosin Beta-4 and its TB-500 fragment are thought to work in part through actin regulation, meaning they interact with actin, a protein involved in cell structure and movement, in a way that supports cell migration to injury sites. They're also thought to promote angiogenesis, the formation of new blood vessels, which is a plausible pathway for supporting wound and tissue healing more broadly. Both mechanisms are biologically reasonable and consistent with what's been observed in animal studies, but plausibility is a starting hypothesis, not confirmation that the fragment performs the same way in humans.
Evidence Gaps and What Would Strengthen the Case
What's missing is specific: dedicated, peer-reviewed, randomized, controlled human trials conducted on the TB-500 fragment itself, rather than on the different full-length Thymosin Beta-4 molecule. Until that kind of trial exists, claims about TB-500's effects in humans should be understood as extrapolated, drawn from animal data on the fragment and human data on a related but distinct molecule, not clinically confirmed for the fragment specifically.
Regulatory Status
TB-500 is not an FDA-approved drug. It is sold as a research chemical for laboratory research use only. Its regulatory footing is its own, separate from the broader compounding bulk substances discussions that have specifically targeted other research peptides, and readers shouldn't assume TB-500 carries the same regulatory history as those compounds.
Bloodwork to Track
There's no bloodwork marker specific to TB-500. A general safety baseline, a comprehensive metabolic panel and CBC, is a reasonable starting point before and during any protocol involving it. See the peptide bloodwork guide for what a baseline panel typically includes, and the Comprehensive Metabolic Panel and CBC explainers for what each test actually measures.
Related Reading
For dosing and protocol context, see the TB-500 and BPC-157 Stack Guide. For a look at how a related peptide's human evidence picture breaks down, see BPC-157 Human Studies. BioStackIQ's Rate My Stack and Build Protocol can help you think through where a compound like this fits into a broader stack, with this evidence picture in mind.